Kessel, Christoph http://orcid.org/0000-0002-0638-2949
Koné-Paut, Isabelle
Tellier, Stéphanie
Belot, Alexandre
Masjosthusmann, Katja
Wittkowski, Helmut
Fuehner, Sabrina
Rossi-Semerano, Linda
Dusser, Perrine
Marie, Isabelle
Boukhedouni, Nadja
Agostini, Helène
Piedvache, Céline
Foell, Dirk
Funding for this research was provided by:
Horizon 2020 (779295 (ImmunAID))
Westfälische Wilhelms-Universität Münster
Article History
Received: 3 January 2022
Accepted: 30 May 2022
First Online: 14 June 2022
Change Date: 21 August 2022
Change Type: Update
Change Details: Missing Open Access funding information has been added in the Funding Note.
Declarations
:
: Sampling of KAWAKINRA study material was approved in context of the previous trial (NCT02390596). Collection of MIS-C, sJIA-MAS, and HC serum was approved by the local (University Hospital Muenster: 2015–670-f-S) ethical committee and parents or caregivers signed written informed consent.
: All study participants (> 18 years) or (if < 18 years) their parents or caregivers signed written informed consent.
: No individual data (i.e., images, videos, personally identifiable details) are included in this study.
: CK has received consulting fees from Novartis and Swedish Orphan Biovitrum (SOBI) (less than $10,000 each) and receives research support from Novartis; IKP has received consulting fees from AbbVie, Pfizer, Roche, Chugai, Novartis, SOBI, and Novimmune (less than $10,000 each). AB has received research support paid to his institution from AbbVie, Novartis, Pfizer, Roche Chugai, and Merck Serono. HW has received honoraria (lecture fees) from Novartis and Takeda, and travel support from Octapharma and CSL-Behring; DF received speaker fees/honoraria from Chugai-Roche, Novartis, and SOBI as well as research support from Novartis, Pfizer, and SOBI. No other disclosures relevant to this article were reported.